HC Wainwright Boosts Earnings Estimates for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Equities research analysts at HC Wainwright lifted their Q4 2024 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Monday, November 4th. HC Wainwright analyst E. White now anticipates that the biopharmaceutical company will post earnings per share of $0.15 for the quarter, up from their prior forecast of $0.11. HC Wainwright has a "Buy" rating and a $55.00 price objective on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $0.13 per share.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The company had revenue of $83.90 million for the quarter, compared to analysts' expectations of $81.68 million. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business's revenue was down 49.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.73 earnings per share.

Several other research firms have also recently weighed in on TGTX. TD Cowen started coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a "buy" rating and a $50.00 price target for the company. B. Riley raised their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a "buy" rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research note on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $37.67.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $1.31 during trading hours on Wednesday, hitting $27.17. The stock had a trading volume of 4,139,878 shares, compared to its average volume of 3,650,948. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The stock has a market capitalization of $4.21 billion, a price-to-earnings ratio of -258.60 and a beta of 2.19. TG Therapeutics has a one year low of $9.81 and a one year high of $27.67. The stock's 50-day moving average price is $23.57 and its two-hundred day moving average price is $20.26.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% in the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares during the last quarter. Blue Trust Inc. lifted its stake in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock worth $35,000 after purchasing an additional 849 shares during the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics during the second quarter valued at approximately $35,000. ORG Wealth Partners LLC purchased a new position in shares of TG Therapeutics during the third quarter valued at approximately $53,000. Finally, Values First Advisors Inc. bought a new position in shares of TG Therapeutics during the third quarter valued at approximately $58,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.